FindTrial
Sign In

Does EUS-FNA in different sites of pancreatic carcinoma can less the passes on diagnostic yields?

EUS-FNA performed along the edge of lesion may provide a higher diagnostic yield of pancreatic adenocarcinomas

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-13004772
Enrollment
Unknown
Registered
2013-02-18
Start date
2013-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic carcinoma

Interventions

Gold Standard:
Index test:

Sponsors

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. diagnosed or suspected solid pancreatic lesions according to clinical evaluation and other imaging studies; 2. long axis=2 cm.

Exclusion criteria

Exclusion criteria: 1. cystic pancreatic lesions, the size of lesions 1.5) or thrombocytopenia (platelet count <50,000), inability to sample the lesion because of the presence of intervening blood vessels.

Design outcomes

Primary

MeasureTime frame
cytological parameters;diagnostic accuracy;—

Countries

Japan

Contacts

Public ContactZhu Qi

Department of Gastroenterology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

zhuqi@medmail.com.cn+86 13601892018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026